Abstract

The incidence of head and neck squamous cell carcinoma (HNSC) is increasing year by year. The nerve is an important component of the tumor microenvironment, which has a wide range of cross-talk with tumor cells and immune cells, especially in highly innervated organs, such as head and neck cancer and pancreatic cancer. However, the role of cancer-nerve cross-talk-related genes (NCCGs) in HNSC is unclear. In our study, we constructed a prognostic model based on genes with prognostic value in NCCGs. We used Pearson’s correlation to analyze the relationship between NCCGs and immune infiltration, microsatellite instability, tumor mutation burden, drug sensitivity, and clinical stage. We used single-cell sequencing data to analyze the expression of genes associated with stage in different cells and explored the possible pathways affected by these genes via gene set enrichment analysis. In the TCGA-HNSC cohort, a total of 23 genes were up- or downregulated compared with normal tissues. GO and KEGG pathway analysis suggested that NCCGs are mainly concentrated in membrane potential regulation, chemical synapse, axon formation, and neuroreceptor-ligand interaction. Ten genes were identified as prognosis genes by Kaplan-Meier plotter and used as candidate genes for LASSO regression. We constructed a seven-gene prognostic model (NTRK1, L1CAM, GRIN3A, CHRNA5, CHRNA6, CHRNB4, CHRND). The model could effectively predict the 1-, 3-, and 5-year survival rates in the TCGA-HNSC cohort, and the effectiveness of the model was verified by external test data. The genes included in the model were significantly correlated with immune infiltration, microsatellite instability, tumor mutation burden, drug sensitivity, and clinical stage. Single-cell sequencing data of HNSC showed that CHRNB4 was mainly expressed in tumor cells, and multiple metabolic pathways were enriched in high CHRNB4 expression tumor cells. In summary, we used comprehensive bioinformatics analysis to construct a prognostic gene model and revealed the potential of NCCGs as therapeutic targets and prognostic biomarkers in HNSC.

Highlights

  • Head and neck squamous cell carcinoma (HNSC) is the sixth most common cancer in the world, with 890,000 new cases and 450,000 deaths in 2018 [1]

  • We summarized the incidence of copy body mutation and somatic mutation of NCCGs in HNSC (Figure 1B)

  • The results showed that the high expression of CHRNA1, CHRNA5, CHRNB4, CHRND, CHRNG, and LICAM and the low expression of CHRNA6, GFRA2, GRIN3A, and NTRK1 in HNSC associated with a poor prognosis

Read more

Summary

Introduction

Head and neck squamous cell carcinoma (HNSC) is the sixth most common cancer in the world, with 890,000 new cases and 450,000 deaths in 2018 [1]. The incidence of HNSC continues to rise and is forecasted to increase by 30% in 10 years [2]. Radiotherapy, chemotherapy, and immunotherapy are the main methods for the treatment of HNSC [3]. The 5-year survival rate of HNSC has improved, reaching 66% at the beginning of the twenty-first century [4]. Previous studies have shown that PIK3CA, TP53, CDKN2A, and other genes play an important role in the occurrence and development of HNSC [5]. The research on prognostic gene signatures of HNSC is far from enough, and it is of great significance to explore the molecular mechanism of HNSC

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.